Cognition Therapeutics CEO Issues Letter to Shareholders Cognition Therapeutics (Nasdaq: CGTX) reported progress advancing zervimesine (CT1812) toward late‑stage development for DLB psychosis and continuing Alzheimer's programs. Key facts: $80 million fully funded Phase 2 START trial of 545 participants; START readout expected in H2 2027. SHIMMER and SHINE Phase 2 data showed strong effects, including a 95% reduction in cognitive decline for participants with low p‑tau217. Company plans FDA discussions for a registrational DLB psychosis path in Q2 2026 and will evaluate next steps after START results.

#CGTX Cognition Therapeutics CEO Issues Letter to Shareholders

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update Cognition Therapeutics (Nasdaq: CGTX) reported 2025 results and clinical updates for zervimesine (CT1812). Cash and equivalents were approximately $37.0M with $35.7M in obligated NIH grant funds; company estimates runway through Q2 2027. START (545-patient) enrollment completed; SHIMMER Phase 2 showed therapeutic responses in DLB psychosis. A mid-2026 meeting with the FDA Division of Psychiatry is planned to align on a registrational plan for DLB psychosis. 2025 net loss was $23.5M (basic and diluted $(0.32)).

#CGTX Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

www.stocktitan.net/news/CGTX/cognition-ther...

The #CGTX team is presenting an analysis at #ADPD2026 showing that Phase 2 'SHIMMER' #DLB participants on #zervimesine had a 102% slowing of decline relative to placebo. #Pressrelease: tinyurl.com/26rh26be

#DementiaWithLewyBodies #LewyBodyDementia #Dementia #LewyStrong #Psychosis #Neuroscience

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 Cognition Therapeutics (NASDAQ: CGTX) presented Phase 2 SHIMMER data for zervimesine (CT1812) at AD/PD 2026 (March 17-21, 2026) showing an 86% slowing of decline on NPI-12 versus placebo in dementia with Lewy bodies (DLB).The analysis showed treatment effects across neuropsychiatric, cognitive, motor, and global domains and reported directionally favorable impacts on cognitive fluctuations, memory, movement, and activities of daily living. The company said it plans development of zervimesine for DLB psychosis following a recent FDA Type C meeting.

#CGTX Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat

#CGTX Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies Cognition Therapeutics (NASDAQ: CGTX) announced its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies has reached full enrollment. Each participant will receive 100 mg oral zervimesine daily for up to one year. The program enrollment was completed in three months and was enabled by a donation from a family of a Phase 2 SHIMMER study participant.The company has aligned with FDA on a registrational program for Alzheimer’s disease and has scheduled a Type C meeting with FDA for the second half of January to discuss a proposed Phase 3 program in DLB; meeting minutes are expected after the meeting.

#CGTX Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference Cognition Therapeutics (NASDAQ: CGTX) presented a Phase 3 registrational plan for zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at CTAD on Dec 1, 2025. The company discussed design with the FDA during a July 2025 end-of-Phase 2 meeting and plans an EMA scientific advice meeting in February 2026 to align global strategy.Key design elements: two randomized 1:1 six-month Phase 3 studies of 100 mg oral zervimesine daily, enrichment for patients with lower plasma p-tau217 at screening, efficacy measured by the iADRS, and eligibility for an open-label extension. Phase 2 SHINE data cited a 95% slowing of cognitive decline by ADAS-Cog11 in the lower p-tau subgroup versus placebo.

#CGTX Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Cognition Therapeutics (NASDAQ: CGTX) announced completion of target enrollment for the randomized, placebo‑controlled Phase 2 START study of zervimesine (CT1812) in mild cognitive impairment and early Alzheimer’s disease, reaching 540 participants.Approximately 50% of participants were enrolled during the last six months and ~15% of randomized participants were receiving background infusions of Leqembi (lecanemab) or Kisunla (donanemab). Topline results are expected after all participants complete 18 months of treatment.

#CGTX Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

www.stocktitan.net/news/CGTX/cognition-ther...

#CGTX Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

www.stocktitan.net/news/CGTX/cognition-ther...

Leading Indicators, Monday September 22, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Mon Sept 22nd - #FISI #EQ #DFDV #CGTX #BETR #ABOS #TWI #UTL #SDHC #RFI #PSFE #VTSI #MAGN #LZB #HOUS #GMRE #FBRT #ETD #DX #CHMI #BBT #ARR - More: crystalequityresearch.com/leading-indi... - #smallcap

540-Patient Alzheimer's Trial: Cognition's Once-Daily Oral Drug Zervimesine Reaches Major Milestone Cognition's Phase 2 START Study for early Alzheimer's drug zervimesine achieves 75% enrollment of 540 patients. Trial follows successful SHINE study showing cognitive decline reduction.

#CGTX Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

www.stocktitan.net/news/CGTX/cognition-ther...

🚀 Exciting times for #CGTX! Trading at $2.44, a $30M direct offering fuels growth and drug pipeline advancements. Bullish momentum with 10-day SMA at $2.40 & 8-day EMA at $2.47. Consider entering at $2.40, targeting $2.60 & $2.80. Stop loss: $2.20. #BiotechBoom 📈

🚀 Exciting times for #CGTX! With a $30M boost, Cognition Therapeutics is set to advance Phase 3 programs. Bullish signals: 8-day EMA at $2.47, MACD momentum, but watch RSI near 64. Consider entry at $2.40, target $2.60/$2.80. Stay alert for trial news! 📈 #FeetrAI

🚨 Exciting times for #CGTX! Trading at $2.44, recent $30M offering might shake things up. Mixed signals: 10-day SMA hints support, MACD shows bullish vibes, but RSI is neutral. Market's cautious, so watch those Phase 3 trials! 🎯 Short target: $2.30/$2.20, stop: $2.55. 📉 #BiotechBuzz #FeetrAI

🚀 Exciting times for #CGTX! After a $30M boost for Phase 3 drug programs, investor confidence is soaring. With bullish technicals and a price above key averages, it's primed for growth. Consider entering at $2.50 with targets at $2.70 & $2.90. Manage risk wisely! 📈 #BiotechBoom

$30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug Biotech firm Cognition Therapeutics (NASDAQ: CGTX) secures $30M from two institutional investors to fund Phase 3 programs of zervimesine for neurodegenerative disorders. Closing expected Aug 29.

#CGTX Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/CGTX/cognition-ther...

Most Searched, Monday August 25, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Aug 25th - #STSS #CGTX #CIFR #ATAI #VRNT #ETHZ #HIVE #ONDS #BBAI #RR #HCWB #ASST #THM #THAR #MGNI #LIDR #INHD #CBRL #ASM #AEHR - More: crystalequityresearch.com/most-searche... - #smallcap

Click Subscribe #CognitionTherapeutics #CGTX #FDA #Phase3 #Alzheimers

Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy Cognition's Zervimesine slows cognitive decline by 95% in targeted Alzheimer's patients. FDA supports innovative blood-test screening approach for Phase 3 trials. Learn more.

#CGTX Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

www.stocktitan.net/news/CGTX/cognition-ther...

Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs New clinical data reveals 28.6% reduction in disease progression. FDA breakthrough designation pending. Multiple trial milestones achieved across neurology programs. See results.

#CGTX Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

www.stocktitan.net/news/CGTX/cognition-ther...

Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia New clinical data reveals 86% improvement in DLB symptoms and significant Alzheimer's benefits. Blood test predicts patient response to zervimesine treatment. See full results.

#CGTX Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease Cognition Therapeutics (NASDAQ: CGTX) has published results from their Phase 2 'SEQUEL' study analyzing the proteomic effects of zervimesine (CT1812) in Alzheimer's disease patients. The study demonstrated that zervimesine treatment showed promising trends in normalizing brain electrical activity and improving communication between brain regions.The research revealed that zervimesine helps preserve neuronal health under disease conditions by affecting proteins involved in vesicle formation, exocytosis, and endosomal trafficking. In vitro experiments showed that zervimesine protected neurons from oxidative stress-induced death, maintaining cellular integrity and preventing the release of neurofilament light (NfL) protein, a marker of neuronal damage.These findings support previous results from the company's 'SHINE' Study and suggest a potential neuroprotective mechanism for zervimesine in treating Alzheimer's disease.

#CGTX Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

www.stocktitan.net/news/CGTX/cognition-ther...

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC Cognition Therapeutics (NASDAQ: CGTX) announced significant positive results from their Phase 2 'SHIMMER' study of zervimesine (CT1812) in treating dementia with Lewy bodies (DLB). The drug demonstrated remarkable efficacy with treatment improvements of 86% in behavioral outcomes, 52% in daily living activities, 91% in cognitive fluctuations, and 62% in motor symptoms compared to placebo.Additionally, in the Phase 2 'SHINE' study for Alzheimer's disease, zervimesine showed promising results, particularly in patients with lower p-Tau217 levels, demonstrating a 95% slowing of cognitive decline at six months compared to placebo. Dr. James E. Galvin will present these findings at the Alzheimer's Association International Conference (AAIC) on July 29, 2025.

#CGTX Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

www.stocktitan.net/news/CGTX/cognition-ther...

#CGTX #CognitionTherapeutics takes a major step forward in the fight against Alzheimer’s. The company has completed its End-of-Phase 2 meeting with the FDA for Zervimesine (CT1812), advancing closer to a pivotal Phase 3 trial.
prismmarketview.com/cognition-th...

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease Cognition Therapeutics (NASDAQ: CGTX) has completed a crucial end-of-Phase 2 meeting with the FDA regarding zervimesine (CT1812), their Alzheimer's disease treatment candidate. The meeting, held on July 9, 2025, focused on reviewing Phase 2 'SHINE' study results and discussing the proposed Phase 3 program requirements for a potential new drug application (NDA).CEO Lisa Ricciardi indicated a positive outcome from the discussions, with the company expecting to receive the FDA's formal minutes in August 2025 to confirm their development pathway for zervimesine in Alzheimer's treatment.

#CGTX Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

www.stocktitan.net/news/CGTX/cognition-ther...